Therapeutic Implications of Germline Testing in Patients With Advanced Cancers
暂无分享,去创建一个
N. Schultz | M. Ladanyi | M. Berger | A. Drilon | K. Offit | M. Morris | D. Solit | M. Robson | D. Chakravarty | Ritika Kundra | Hongxin Zhang | O. Ceyhan-Birsoy | A. Zehir | Z. Stadler | D. Mandelker | G. Jayakumaran | J. Galle | W. Abida | A. Varghese | C. Aghajanian | E. Salo-Mullen | K. Cadoo | M. Carlo | Y. Kemel | K. Tkachuk | B. Nguyen | M. Walsh | E. O’Reilly | N. Abu-Rustum | Christopher J. Fong | L. Diaz | Shaleigh A. Smith | Ying L. Liu | M. Sheehan | A. Maio | Alicia Latham | Amanda Erakky | Shaleigh A Smith | Bastien Nguyen | Alicia J Latham
[1] E. Winer,et al. TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] David J. Sims,et al. Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH) , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] N. Schultz,et al. Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection , 2020, Clinical Cancer Research.
[4] Mark W. Ball,et al. Results from a phase II study of bevacizumab and erlotinib in subjects with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) or sporadic papillary renal cell cancer. , 2020, Journal of Clinical Oncology.
[5] F. Saad,et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer. , 2020, The New England journal of medicine.
[6] S. Friedman,et al. NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020. , 2020, Journal of the National Comprehensive Cancer Network : JNCCN.
[7] Alex H. Wagner,et al. A harmonized meta-knowledgebase of clinical interpretations of somatic genomic variants in cancer , 2020, Nature Genetics.
[8] Seth M Steinberg,et al. Selumetinib in Children with Inoperable Plexiform Neurofibromas. , 2020, The New England journal of medicine.
[9] F. Feng,et al. Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study , 2020, Clinical Cancer Research.
[10] A. Drilon,et al. Registrational results of LOXO-292 in patients with RET-altered thyroid cancers , 2019, Annals of Oncology.
[11] B. Monk,et al. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. , 2019, The New England journal of medicine.
[12] N. Socci,et al. Tumour lineage shapes BRCA-mediated phenotypes , 2019, Nature.
[13] Joon-Oh Park,et al. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. , 2019, The New England journal of medicine.
[14] Ahmet Zehir,et al. Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] A. Shaw,et al. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. , 2018, The Lancet. Oncology.
[16] Gabe S. Sonke,et al. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer , 2018, The New England journal of medicine.
[17] W. Eiermann,et al. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation , 2018, The New England journal of medicine.
[18] M. Ahn,et al. CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3). , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] David R. Jones,et al. Frequency of actionable cancer predisposing germline mutations in patients with lung cancers. , 2018 .
[20] Ying Cheng,et al. Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.
[21] S. Loi,et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. , 2017, The New England journal of medicine.
[22] C. Caldwell,et al. Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor Abemaciclib. , 2017, Cancer cell.
[23] P. Kantoff,et al. Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing , 2017, JAMA.
[24] Ludmila V. Danilova,et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade , 2017, Science.
[25] Robert J. Lonigro,et al. Integrative Clinical Genomics of Metastatic Cancer , 2017, Nature.
[26] Michael P. Schroeder,et al. Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations , 2017, Genome Medicine.
[27] Moriah H Nissan,et al. OncoKB: A Precision Oncology Knowledge Base. , 2017, JCO precision oncology.
[28] Edward S. Kim,et al. Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] Donavan T. Cheng,et al. Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients , 2017, Nature Medicine.
[30] P. Stephens,et al. Clinical Benefit in Response to Palbociclib Treatment in Refractory Uterine Leiomyosarcomas with a Common CDKN2A Alteration. , 2017, The oncologist.
[31] B. Taylor,et al. Implementing Genome-Driven Oncology , 2017, Cell.
[32] W. Chung,et al. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics , 2016, Genetics in Medicine.
[33] Steven J. M. Jones,et al. CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer , 2017, Nature Genetics.
[34] Marcin Imielinski,et al. The cancer precision medicine knowledge base for structured clinical-grade mutations and interpretations , 2016, J. Am. Medical Informatics Assoc..
[35] N. Ratner,et al. Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas. , 2016, The New England journal of medicine.
[36] Marian Harris,et al. Institutional implementation of clinical tumor profiling on an unselected cancer population. , 2016, JCI insight.
[37] Ignace Vergote,et al. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. , 2016, The New England journal of medicine.
[38] F. D. De Braud,et al. Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapy , 2016, Drug design, development and therapy.
[39] R. Yelensky,et al. Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study. , 2016, Cancer research.
[40] T. Powles,et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. , 2016, The Lancet. Oncology.
[41] Tao Wang,et al. Diagnostic Yield of Clinical Tumor and Germline Whole-Exome Sequencing for Children With Solid Tumors. , 2016, JAMA oncology.
[42] Anuradha Lakshminarayana,et al. The clinical trial landscape in oncology and connectivity of somatic mutational profiles to targeted therapies , 2016, Human Genomics.
[43] Li Ding,et al. Germline Mutations in Predisposition Genes in Pediatric Cancer. , 2015, The New England journal of medicine.
[44] B. Vogelstein,et al. PD-1 blockade in tumors with mismatch repair deficiency. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] C. Boshoff,et al. Molecular Pathways: Targeting the Cyclin D–CDK4/6 Axis for Cancer Treatment , 2015, Clinical Cancer Research.
[46] P. Jänne,et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. , 2015, The New England journal of medicine.
[47] H. Rehm,et al. Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.
[48] E. Letouzé,et al. SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma , 2014, International journal of cancer.
[49] D. Matei,et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. , 2014, The Lancet. Oncology.
[50] S. Fox,et al. Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines , 2014, Pigment cell & melanoma research.
[51] L. Qin,et al. Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[52] E. Thiele,et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial , 2013, The Lancet.
[53] Kris Chang,et al. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. , 2012, The New England journal of medicine.
[54] K. Owzar,et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.